NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 169.3

Change

-5.70 (-3.26)%

Market Cap

USD 0.67B

Volume

1.73M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+4.57 (+1.09%)

USD 34.03B
ILMN Illumina Inc

+7.53 (+5.51%)

USD 21.57B
ICLR ICON PLC

-0.23 (-0.11%)

USD 17.53B
EXAS EXACT Sciences Corporation

+2.01 (+3.56%)

USD 10.65B
MEDP Medpace Holdings Inc

+1.14 (+0.32%)

USD 10.55B
RDNT RadNet Inc

-2.19 (-3.18%)

USD 5.28B
GH Guardant Health Inc

+1.40 (+3.80%)

USD 4.54B
SHC Sotera Health Co

-0.02 (-0.15%)

USD 3.71B
VCYT Veracyte Inc

+1.24 (+2.99%)

USD 3.11B
NEOG Neogen Corporation

+0.28 (+2.22%)

USD 2.65B

ETFs Containing NTRA

CURG:LSE VanEck Genomics and Healt.. 6.20 % 0.00 %

-0.21 (-2.25%)

USD 4.94M
GNOM Global X Genomics & Biote.. 5.99 % 0.00 %

-0.10 (-2.25%)

USD 0.07B
GNOG:LSE Global X Genomics & Biote.. 5.72 % 0.00 %

-0.10 (-2.25%)

USD 9.55M
GN0M:XETRA Global X Genomics & Biote.. 5.55 % 0.00 %

-0.10 (-2.25%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.55 % 0.00 %

-0.23 (-2.25%)

USD 9.45M
EKG First Trust Nasdaq Lux Di.. 5.25 % 0.00 %

-0.11 (-2.25%)

USD 2.64M
ARCG:LSE ARK Genomic Revolution UC.. 5.24 % 0.00 %

-7.28 (-2.25%)

USD 4.24M
ARKG:LSE ARK Genomic Revolution UC.. 5.24 % 0.00 %

-0.10 (-2.25%)

USD 4.24M
CURE:XETRA VanEck Genomics and Healt.. 4.55 % 0.00 %

-0.24 (-2.25%)

N/A
FBT:LSE First Trust Global Funds .. 4.49 % 0.00 %

+41.20 (+-2.25%)

USD 8.11M
FBTU:LSE First Trust Global Funds .. 4.49 % 0.00 %

+0.41 (+-2.25%)

USD 8.11M
WBIO:LSE WisdomTree BioRevolution .. 4.16 % 0.00 %

-8.50 (-2.25%)

USD 0.45M
WDNA WisdomTree BioRevolution .. 3.97 % 0.00 %

+0.07 (+-2.25%)

USD 2.18M
WRNA:XETRA WisdomTree BioRevolution .. 3.87 % 0.00 %

-0.35 (-2.25%)

USD 2.77M
CURE:AU ETFS S&P Biotech ETF 3.33 % 0.00 %

-1.55 (-2.25%)

USD 0.04B
CDNA:CA CI Bio-Revolution Index E.. 2.83 % 0.00 %

-0.22 (-2.25%)

CAD 6.46M
XMLH:F Legal & General Ucits Etf.. 2.46 % 0.00 %

-0.08 (-2.25%)

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 2.46 % 0.00 %

-0.01 (-2.25%)

USD 0.06B
FXH First Trust Health Care A.. 2.41 % 0.63 %

+1.50 (+-2.25%)

USD 1.07B
2B78:XETRA iShares Healthcare Innova.. 2.37 % 0.00 %

+0.03 (+-2.25%)

USD 1.14B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

-0.15 (-2.25%)

N/A
HEAL:SW iShares Healthcare Innova.. 2.17 % 0.00 %

-0.15 (-2.25%)

N/A
ZHU:CA BMO Equal Weight US Healt.. 1.96 % 0.00 %

+0.38 (+-2.25%)

CAD 0.01B
HTEC Robo Global® Healthcare .. 1.87 % 0.00 %

+0.03 (+-2.25%)

USD 0.05B
DOCG:LSE L&G Healthcare Breakthrou.. 1.82 % 0.00 %

-1.95 (-2.25%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.82 % 0.00 %

-0.02 (-2.25%)

USD 0.07B
EDGE:CA Evolve Innovation Index F.. 1.50 % 0.60 %

-0.14 (-2.25%)

CAD 0.04B
QQQJ Invesco NASDAQ Next Gen 1.. 1.41 % 0.00 %

+0.03 (+-2.25%)

USD 0.66B
STXM EA Series Trust 0.52 % 0.00 %

+0.19 (+-2.25%)

USD 0.01B
FSMD Fidelity Small-Mid Factor 0.49 % 0.00 %

+0.31 (+-2.25%)

USD 0.66B
VISM:AU Vanguard MSCI Internation.. 0.24 % 0.00 %

-0.91 (-2.25%)

USD 0.29B
ZPRS:F SSgA SPDR ETFs Europe II .. 0.23 % 0.00 %

-0.22 (-2.25%)

USD 0.83B
WOSC:SW SPDR® MSCI World Small C.. 0.23 % 0.00 %

-0.01 (-2.25%)

USD 0.95B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

-0.28 (-2.25%)

USD 1.04B
BBH VanEck Biotech ETF 0.00 % 0.35 %

+1.58 (+-2.25%)

USD 0.40B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

-0.06 (-2.25%)

CAD 0.01B
FNX First Trust Mid Cap Core .. 0.00 % 0.62 %

+1.16 (+-2.25%)

USD 1.26B
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

+0.08 (+-2.25%)

USD 0.40B
GVIP Goldman Sachs Hedge Indus.. 0.00 % 0.45 %

-0.22 (-2.25%)

USD 0.32B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.96 (-2.25%)

USD 0.82B
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

-0.66 (-2.25%)

USD 0.12B
BTEC 0.00 % 0.42 %

N/A

N/A
VBK Vanguard Small-Cap Growth.. 0.00 % 0.07 %

+0.71 (+-2.25%)

USD 20.12B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

N/A

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.02 (-2.25%)

N/A
IS0R:F iShares High Yield Corpor.. 0.00 % 0.00 %

+0.38 (+-2.25%)

N/A
IS0R:XETRA iShares $ High Yield Corp.. 0.00 % 0.00 %

-0.08 (-2.25%)

USD 2.71B
IUSN:XETRA iShares MSCI World Small .. 0.00 % 0.00 %

-0.01 (-2.25%)

USD 3.82B
ZPRS:XETRA SPDR MSCI World Small Cap.. 0.00 % 0.00 %

-0.12 (-2.25%)

USD 0.83B
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

-0.01 (-2.25%)

USD 0.07B
BBMC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

+0.59 (+-2.25%)

USD 1.91B
BKMC BNY Mellon US Mid Cap Cor.. 0.00 % 0.00 %

+0.70 (+-2.25%)

USD 0.53B
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

-0.29 (-2.25%)

N/A
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

-0.22 (-2.25%)

USD 0.08B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
ATFV Alger 35 ETF 0.00 % 0.00 %

-0.26 (-2.25%)

USD 0.03B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

+0.06 (+-2.25%)

N/A
CVRT Calamos ETF Trust 0.00 % 0.00 %

-0.37 (-2.25%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.95% 77% C+ 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.95% 77% C+ 86% B+
Trailing 12 Months  
Capital Gain 178.04% 96% N/A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 178.04% 96% N/A 96% N/A
Trailing 5 Years  
Capital Gain 385.94% 100% F 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 385.94% 100% F 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 51.12% 81% B- 87% B+
Dividend Return 51.12% 81% B- 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 92.88% 38% F 23% F
Risk Adjusted Return 55.04% 94% A 80% B-
Market Capitalization 0.67B 98% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 25.19 5% 6%
Price / Cash Flow Ratio -89.60 98% 97%
Price/Free Cash Flow Ratio -26.80 95% 95%
Management Effectiveness  
Return on Equity -25.82% 61% 41%
Return on Invested Capital -40.66% 51% 26%
Return on Assets -9.96% 58% 34%
Debt to Equity Ratio 36.97% 52% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector